Summary

Overview
Global helicobacter pylori infection therapeutics market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
H. pylori (Helicobacter pylori) are bacteria that can cause an infection in the stomach or duodenum. It is the most common cause of peptic ulcer disease. H. pylori can also inflame and irritate the stomach lining (gastritis). Untreated, long-term H. pylori infection can lead to stomach cancer. H. pylori can spread from person to person. H. pylori are found in saliva, plaque on teeth and poop.
H. pylori infections are usually treated with at least two different antibiotics at once. This helps prevent the bacteria from developing a resistance to one particular antibiotic. One newer medication, Talicia, combines two antibiotics (rifabutin and amoxicillin) with a proton pump inhibitor (omeprazole) into a single capsule.
Market Dynamics: Drivers
Increasing adoption of combination therapeutics
The increasing adoption of combination therapeutics is expected to drive the market over the forecast period. Helicobacter pylori can be eradicated with the use of antibiotics, however, more than 1 agent has to be used in combination with either a proton pump inhibitor or bismuth to achieve eradication rates of 90% or greater.
The emergence of antibiotic resistance in H. pylori strains has become a significant concern. Combining different antibiotics with complementary mechanisms of action can improve the effectiveness of treatment and reduce the risk of resistance development.
For instance, on April 26, 2023, Akums Drugs and Pharmaceutical launched its latest formulation, a unique Combikit – (Amoxicillin + Clarithromycin + Esomeprazole). Combikit (Amoxicillin + Clarithromycin + Esomeprazole) is approved by the Central Drugs Standard Control Organisation (CDSCO) for the healing of duodenal ulcers associated with Helicobacter pylori (H. pylori) and eradication of H. pylori in patients with active or healed peptic ulcer.
This Combikit is a combination of three effective drugs - Amoxicillin, Clarithromycin and Esomeprazole. This combination works by inhibiting the growth of H. pylori bacteria and reducing the production of gastric acid. The drug is available in a patient-convenient pack for a complete course of therapy.
The emergence of antibiotic resistance in H. pylori strains has become a significant concern. Combining different antibiotics with complementary mechanisms of action can improve the effectiveness of treatment and reduce the risk of resistance development. Combining antibiotics with proton pump inhibitors (PPIs) and bismuth-containing compounds has been shown to enhance the eradication rates of H. pylori. This approach is often referred to as triple therapy (two antibiotics plus a PPI or bismuth) or quadruple therapy (three antibiotics plus a PPI or bismuth).
For instance, on March 17, 2023, Par, an Endo company, is offering the first generic version of Allergan's Pylera (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) 40 mg, 125 mg and 125 mg capsules. Bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules, combined with omeprazole are indicated for treating patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past five years) to eradicate H. pylori.
Further, the increasing prevalence of helicobacter pylori infection, rising regulatory approvals, increasing clinical trials for more effective therapeutics, increasing awareness about the condition and therapeutics and increasing advancements in the development of novel drugs and therapies are the factors expected to drive the market over the forecast period.
Restraints
Factors such as side effects associated with the various therapeutics, complications such as increased risk of short-term cardiovascular mortality and the high cost associated with some therapeutics are the factors expected to hamper the market.
Segment Analysis
The global helicobacter pylori infection therapeutics market is segmented based on disease type, therapeutics, distribution channel and region.
The antibiotics segment accounted for approximately 59.6% of the helicobacter pylori infection therapeutics market share
The antibiotics segment is expected to hold the largest market share over the forecast period. Usually, two antibiotics are prescribed. Among the common choices are amoxicillin, clarithromycin (Biaxin), metronidazole (Flagyl) and tetracycline. H. pylori infections are usually treated with at least two different antibiotics at once. This helps prevent the bacteria from developing a resistance to one particular antibiotic.
H. pylori is a bacterial species that colonizes the stomach lining. Antibiotics are effective against bacterial infections, making them a logical choice for treating H. pylori. H. pylori has shown the ability to develop resistance to certain antibiotics. Using a combination of antibiotics in therapy helps reduce the risk of antibiotic resistance and increases the chances of successful bacterial eradication. The antibiotics kill the H. pylori bacteria and the acid-suppressing medicine reduces stomach acid, so any ulcers can heal. Antibiotics are also very effective by combining with other classes of drugs such as proton pump inhibitors.
For instance, on March 15, 2020, RedHill Biopharma launched Talicia(a combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole)), a delayed-release capsule for treating Helicobacter pylori (H. pylori) infection in adults.
Geographical Analysis
North America accounted for approximately 42.5% of the market share
North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and the increasing prevalence of H.Pylori. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies. This strong presence of major players actively performing in research activities leads to the launch of novel therapeutics for the eradication of Helicobacter pylori.
For instance, on October 30, 2023, Phathom Pharmaceuticals, Inc. cleared the U.S. Food and Drug Administration (FDA) approval of the Prior Approval Supplement (PAS) for the reformulation of vonoprazan tablets for both VOQUEZNA TRIPLE PAK (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA DUAL PAK (vonoprazan tablets, amoxicillin capsules), for the treatment of Helicobacter pylori (H. pylori) infection in adults. VOQUEZNA treatment regimens contain antibiotics conveniently packaged with vonoprazan and the first innovative acid suppressant from a new drug class approved in the U.S. in over 30 years.
Furthermore, there is an increasing prevalence of H. pylori infections in North America especially in the United States and factors such as lifestyle, socioeconomic status and healthcare infrastructure can influence the occurrence of these infections. Due to the higher prevalence, there may be a greater demand for H. pylori therapeutics.
For instance, according to the National Institute of Health (NIH), 2021, About 30 to 40% of people in the United States get an H. pylori infection. Most people get it as a child. H. pylori usually does not cause symptoms. But it can break down the inner protective coating in some people's stomachs and cause inflammation. This can lead to gastritis or a peptic ulcer.
Competitive Landscape
The major global players in the helicobacter pylori infection therapeutics market include Phathom Pharmaceuticals, Akums Drugs & Pharmaceuticals Ltd., RedHill Biopharma Ltd., Cumberland Pharmaceuticals Inc., Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, Pernix Therapeutics LLC, Astellas Pharma Inc., Faromed Lifesciences LLP and Matrix Pharma among others.
COVID-19 Impact Analysis
The COVID-19 pandemic significantly impacted the global helicobacter pylori infection therapeutics market. Helicobacter pylori (H. pylori) is affecting half of the globe. The misuse of antibiotics during the coronavirus disease 2019 (COVID-19) pandemic time can affect H. pylori eradication rates. As the COVID-19 pandemic has moved forward fast, high resistance rates of H. pylori to both clarithromycin and levofloxacin were developed less than two years from the start of the pandemic. The pandemic also disrupted the supply chain of these therapeutics globally.
Market Segmentation
By Disease Type
• Type I H. Pylori
• Type II H. Pylori
By Therapeutics
• Antibiotics
o Amoxicillin
o Clarithromycin (Biaxin)
o Metronidazole (Flagyl)
o Tetracycline
o Others
• Proton Pump Inhibitors (PPIs)
o Lansoprazole (Prevacid)
o Omeprazole (Prilosec)
o Pantoprazole (Protonix)
o Rabeprazole (Aciphex)
o Esomeprazole (Nexium)
o Others
• Histamine (H-2) Blockers
• Stomach-Lining Protectors
• Bismuth Subsalicylate
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Why Purchase the Report?
• To visualize the global helicobacter pylori infection therapeutics market segmentation based on disease type, therapeutics, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of helicobacter pylori infection therapeutics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global helicobacter pylori infection therapeutics market report would provide approximately 61 tables, 59 figures and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Therapeutics
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Adoption of Combination Therapeutics
4.1.2. Restraints
4.1.2.1. Side Effects Associated with the Various Drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. Patent Analysis
5.8. SWOT Analysis
5.9. PESTEL Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Type I H. Pylori*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Type II H. Pylori
8. By Therapeutics
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
8.1.2. Market Attractiveness Index, By Therapeutics
8.2. Antibiotics*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Amoxicillin
8.2.4. Clarithromycin (Biaxin)
8.2.5. Metronidazole (Flagyl)
8.2.6. Tetracycline
8.2.7. Others
8.3. Proton Pump Inhibitors (PPIs)
8.3.1. Lansoprazole (Prevacid)
8.3.2. Omeprazole (Prilosec)
8.3.3. Pantoprazole (Protonix)
8.3.4. Rabeprazole (Aciphex)
8.3.5. Esomeprazole (Nexium)
8.3.6. Others
8.4. Histamine (H-2) Blockers
8.5. Stomach-Lining Protectors
8.6. Bismuth Subsalicylate
8.7. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Online Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Phathom Pharmaceuticals*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Akums Drugs & Pharmaceuticals Ltd.
12.3. RedHill Biopharma Ltd.
12.4. Cumberland Pharmaceuticals Inc.
12.5. Eisai Co., Ltd.
12.6. Takeda Pharmaceutical Company Limited
12.7. Pernix Therapeutics LLC
12.8. Astellas Pharma Inc.
12.9. Faromed Lifesciences LLP
12.10. Matrix Pharma
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us